ClinicalTrials.Veeva

Menu

BioPoly® RS Partial Resurfacing Patella Registry Study

B

BioPoly

Status

Completed

Conditions

Cartilage Disease

Treatments

Device: BioPoly RS Partial Resurfacing Patella Implant

Study type

Observational

Funder types

Industry

Identifiers

NCT02991300
1251001 V2.0

Details and patient eligibility

About

The data registry will increase the knowledge of outcomes for treatment of focal cartilage defects of the patella treated with the BioPoly RS Patella Implant and will allow monitoring of the clinical safety and performance of the device and surgical implantation kit

Full description

The data registry will increase the knowledge of outcomes for treatment of focal cartilage defects of the patella treated with the BioPoly RS Patella Implant This study will also allow monitoring of the clinical safety and performance of the device and surgical implantation kit

Enrollment

12 estimated patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 21 years and older
  • Cartilage lesion(s) located in the facets of the patella that have failed prior therapy (conservative or surgical)
  • Symptomatic lesions classified as ICRS grade 2, 3, or 4
  • Lesion size may not exceed 3.1 cm2 and must be circumscribed by a 15 mm or 20 mm circle of normal or nearly normal (ICRS Grade 0 or 1) cartilage, with an overall depth less than 4 mm from the articulating surface
  • Subchondral bone quality sufficient to support the implant
  • Understanding and willingness to comply with the post-operative rehabilitation instructions and follow-up visits.

Exclusion criteria

  • Body mass index (BMI) ≥ 35
  • Generalized degenerative or autoimmune arthritis
  • Gout
  • Uncorrected chronic malalignment of the patella (may be corrected at the same time as the implantation of the BioPoly device).
  • Uncorrected ligamentous instability (may be corrected at the same time as the implantation of the BioPoly device).
  • Kissing lesion on femur
  • More than one implant required to accommodate lesion
  • Allergy to ultra-high molecular weight polyethylene (UHMWPE), or hyaluronan/ hyaluronic acid (HA)
  • Use with opposing articulating femoral components
  • Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee
  • Pregnant, prisoner, vulnerable population, or unable to provide informed consent.

Trial contacts and locations

2

Loading...

Central trial contact

Dinesh Nathwani, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems